Dementia Drugs Market Foreseen to Grow Exponentially over 2026

1. Dementia Drugs - Size, Share, Growth, Outlook, Dementia Drugs - Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 and Opportunity Analysis, 2018-2026 Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer’s disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Accumulation of a protein called beta amyloid, in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in dementia. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1664 Increasing number of pipeline products is expected to drive growth of the dementia drugs market Major factors fueling growth of the dementia drugs market include the large number of drugs in the pipeline, which are expected to enter into the market by 2020-2022. According to the study published by Translational Research and Clinical Intervention, in September 2017, it is recorded that 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint efforts is also boosting growth of the market. For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease. However, failure of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market. For instance, in February 2017, an external data monitoring committee warned that Merck & Co., Inc. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study. Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT to boost demand in emerging economies

2. On the basis of geography, the global dementia drugs market can be segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold the largest market, owing to major approval of drugs in this region and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases, especially in China, India. This in turn, is expected to create lucrative opportunities for growth of the market. For instance, according to Alzheimer’s Disease International Association, in 2015, East Asia is the region with the maximum number of people living with dementia (9.8 million), followed by Western Europe (7.4 million). Report includes chapters which deeply display the following deliverable about industry : • Dementia Drugs Research Objective and Assumption • Dementia Drugs Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Dementia Drugs Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Dementia Drugs, By Regions • Dementia Drugs Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Dementia Drugs Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Dementia Drugs Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Dementia Drugs Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Some of the top companies operating in the dementia drugs market are Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

3. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1664 Detailed Segmentation: Global Dementia Drugs Market, By Drug Class: • MAO Inhibitors • Cholinesterase Inhibitors • Glutamate Inhibitors Global Dementia Drugs Market, By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Others Global Dementia Drugs Market, By Region: • North America • • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com